Charles Ross & Son Appoints New Vice President of Sales
Ken Langhorn, who joined the company in February 1998, will assume the position.
Charles Ross & Son, a mixing equipment, blenders, dispersers, and dryers manufacturing company located in Hauppauge, NY, announced the appointment of Ken Langhorn as the new vice president of sales on Nov. 15, 2019.
According to a company press release, Langhorn joined the company in February 1998 as a lab assistant in the company's Test and Development Center after graduating with a Bachelor of Science degree from Stony Brook University in Stony Brook, NY. There, he worked on the company’s HV Blades, Mega Shear, and Inline SLIM technologies. Langhorn was then promoted to product manager of high shear mixers, high speed dispersers, multi-shaft mixers, and three roll mills in December 1999.
In June 2006, Langhorn was named technical director and managed the Test and Development Center where he worked with customers on more than 150 tests annually and provided support to sales teams and engineering groups throughout the company's United States, China, and India locations until his recent appointment to vice president of sales.
Source: Charles Ross & Son
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
